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© 2014 Jeremy McKinney 
I. Introduction 
 On June 13, 2013, the Supreme Court issued a long-awaited decision in Ass'n for 
Molecular Pathology v. Myriad Genetics, Inc. (a.k.a. the Myriad gene patents case). The Court, 
in a rare unanimous decision, held that “a naturally occurring DNA segment is a product of 
nature and not patent eligible merely because it has been isolated, but that cDNA1 is patent 
eligible because it is not naturally occurring.”2  This ruling upset thirty years of settled 
expectations, as inventors and companies have relied on patent protection for their work in gene 
isolation. This case note will explore the implications of this ruling on future research, and 
innovation in the wake of the Court’s decision. 
II. Law Before the Case 
Congress, in order “[t]o promote the Progress of Science and useful Arts,” was granted the 
power to award inventors’ time limited exclusive rights to their inventions in the U.S. 
                                                          
1 cDNA, COLLINS ENG. DICTIONARY, http://www.collinsdictionary.com/dictionary/english/cdna? 
(last visited June 17, 2014) (abbreviation for “complementary DNA”) (defined as “a form of 
DNA artificially synthesized from a messenger RNA template and used in genetic engineering to 
produce gene clones”). 
2 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111 (2013). 
Constitution.3 To accomplish this, Congress passed the first Patent Act in 1790.4 This initial act 
was followed by several successive acts designed to refine and clarify the original Act,5 finally 
leading to codification of the patent law in 1952 as United States Code Title 35.6 While it is 
similar to and retains the same basic purpose as the original eighteenth century laws, Title 35 
serves as the preeminent structure for today's patent law.7 
The patent law seeks to accomplish the goal of “promot[ing] the Progress of Science and 
useful Arts”8 by granting temporary monopolies to inventors for their innovations. In exchange 
for the monopoly, inventors must release detailed descriptions of their inventions to the public, 
written in language that would allow a person of reasonable skill in the art to understand what is 
                                                          
3 U.S. CONST. art. I, § 8, cl. 8 (“To promote the Progress of Science and useful Arts, by securing 
for limited Times to Authors and Inventors the exclusive Right to their respective Writings and 
Discoveries”). 
4 See Act of Apr. 10, 1790, ch. 7, 1 Stat. 109. The Act authorized patents for “any useful art, 
manufacture, engine, machine, or device, or any improvement therein not before known or used” 
and provided that the Secretary of State, the Secretary of War, and the Attorney General 
determined that the invention was “sufficiently useful and important.” DONALD S. CHISUM, 
CHISUM ON PATENTS § 2 n.12 (1998). 
5 See CHISUM, supra note 4, §§ 2-6. The 1790 Act was replaced with the 1793 Act omitting “the 
important determination and authorized patents for ‘any useful art, machine, manufacture, or 
composition of matter, or any new and useful improvement [thereon], not known or used before 
the application.”’ Id. § 2 (quoting Act of Feb. 21, 1793, ch. 11, 1 Stat. 318). The Patent Act in 
1836 “created a Patent Office and a system of examination of patent applications for compliance 
with the requirement of novelty over the prior art.” Id. § 3 (referring to the Act of July 4, 1836, 
ch. 357, 5 Stat. 117). The 1870 Act replaced the 1836 Act but retained the essential provisions 
and requirements. Id. (referring to the Act of July 8, 1870, ch. 230, 16 Stat. 198). The 1952 Act, 
which was codified as 35 U.S.C., “rearranged existing statutory provisions and stated in statutory 
form matters previously recognized only in court decisions and Patent Office practice” and made 
several change. Id. § 6. 
6 See id. § 6. The 1952 Act “rearranged existing statutory provisions and stated in statutory form 
matters previously recognized only in court decisions and Patent Office practice” and made 
several changes and additions, including a statutory provision on non-obviousness. 
7 See Bonito Boats, Inc. v. Thunder Crafts Boats, Inc., 489 U.S. 141, 148 (1989) (O’Connor, J., 
in dicta) (observing that “[t]oday's patent statute is remarkably similar to the law as known to 
Jefferson in 1793”); CHISUM, supra note 4, § 2 (stating that the 1790 and 1793 patent statutes 
contain fundamental concepts that remain the basis of United States patent law today). 
8 U.S. CONST. srt. I, § 8, cl. 8. 
being claimed.9 These detailed descriptions are the consideration for the monopoly, given by the 
inventor to the public, who then may benefit by the further development of ideas based on the 
new technology.10 The grant of a monopoly and the rights of the public to innovate, require that 
patent claims are clear;11 thus ensuring that the patent owner knows what he owns and the public 
knows what he does not.12 This is part of a delicate balance that the law attempts to maintain 
between inventors who rely on the law for protection of their intellectual property to make the 
invention known, and the public who are encouraged to pursue innovations, creations, and new 
ideas beyond the inventor's exclusive rights.13 
To determine whether a patent claim contains patent-eligible subject matter, courts and 
the United States Patent Office (USPTO), rely on 35 U.S.C. § 101. This section outlines the 
portal through which all innovation must pass en route to patent recognition. The determination 
has been described as a threshold inquiry, which is to be determined as a matter of law in 
establishing the validity of the patent.14 Section 101 places patentable subject matter into four 
                                                          
9 35 U.S.C. § 112 (2012); see also Application of Barker, 559 F.2d 588, 593 (C.C.P.A. 1977) 
(“[W]e reaffirm our recognition that 35 U.S.C. § 112, first paragraph, contains separate 
requirements for a written description (1) of the invention, and (2) of the manner and process of 
making and using it, in such full, clear, concise, and exact terms as to enable any person skilled 
in the art . . . to make and use the same . . . .”) 
10 See Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 607 (1950), (holding that 
disclosure of inventions is one of the primary purposes of the patent system). 
11 35 U.S.C. § 112. 
12 Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 535 U.S. 722, 731 (2002); see 
also McClain v. Ortmayer, 141 U.S. 419, 424 (1891) (holding that requiring the patentee to 
particularly point out, and distinctly claim his invention, is “not only to secure to him all to 
which he is entitled, but to apprise the public of what is still open to them”). 
13 Bonito Boats, 489 U.S. at 150-51 (“The federal patent system thus embodies a carefully 
crafted bargain for encouraging the creation and disclosure of new, useful, and nonobvious 
advances in technology and design in return for the exclusive right to practice the invention for a 
period of years”). 
14 In re Bilski (Bilski I), 545 F.3d 943, 950 (Fed. Cir. 2008) (citing In re Comiskey, 499 F.3d 
1365, 1371 (Fed. Cir. 2007)). 
broad categories, including: “new and useful process[es], machine[s], manufacture, or 
composition[s] of matter.”15  
However, despite the broad nature of the statutory language, the Supreme Court has 
recognized three “fundamental principles” as exceptions to the Patent Act's subject matter 
eligibility requirements: “laws of nature, physical phenomena, and abstract ideas.”16 The 
Supreme Court has held that “[t]he concepts covered by these exceptions are ‘part of the 
storehouse of knowledge of all men . . . free to all men and reserved exclusively to none.’”17 
Therefore, “even if an invention appears to claim subject matter that would be statutorily covered 
by the Patent Act, it will still be denied patent protection if it falls into one of the ‘fundamental 
principles' exceptions.”18 
Although a fundamental principle cannot be patented, the Supreme Court has held that 
“an application of a law of nature or mathematical formula to a known structure or process may 
well be deserving of patent protection,” so long as that application would not preempt 
substantially all uses of the fundamental principle.19 In making a preemption determination, the 
claim must be considered as a whole, as it is “inappropriate to dissect the claims into old and 
new elements and then to ignore the presence of the old elements in the analysis.”20 Nonetheless, 
                                                          
15 35 U.S.C. § 101; see also Bilski v. Kappos, 130 S.Ct. 3218, 3225 (2010); Diamond v. 
Chakrabarty, 447 U.S. 303, 308 (1980). 
16 Bilski, 130 S.Ct. at 3225. 
17 Bilski I, 545 F.3d at 952 (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 
130 (1948)). 
18 CLS Bank Int'l v. Alice Corp. Pty. Ltd., 768 F. Supp. 2d 221, 230 (D.D.C. 2011). 
19 Bilski, 130 S. Ct. at 3230 (quoting Diamond v. Diehr, 450 U.S. 175, 187 (1981)) (internal 
quotations omitted). 
20 Id. 
a scientific principle cannot be made patentable by simply limiting its use “to a particular 
technological environment” or by adding “insignificant post-solution activity.”21  
To determine whether the subject matter of a claim is simply a product of nature, or has 
been remodeled into something more, courts have frequently applied the “machine-or-
transformation” test.22 Under this test, claimed subject matter is patent-eligible pursuant to § 101 
if: (1) it is tied to a particular machine or apparatus; or (2) it transforms a particular article into a 
different state or thing.23 The Federal Circuit further explained: 
A claimed process involving a fundamental principle that uses a particular 
machine or apparatus would not pre-empt uses of the principle that do not also use 
the specified machine or apparatus in the manner claimed. And a claimed process 
that transforms a particular article to a specified different state or thing by 
applying a fundamental principle would not preempt the use of the principle to 
transform any other article, to transform the same article but in a manner not 
covered by the claim, or to do anything other than transform the specified 
article.24 
This test has guided many courts in their gatekeeping function, however, the Supreme Court 
recently held that, although the machine or transformation test remains a “useful and important 
clue,” it is not the sole test for determining the patent-eligibility of process claims.25 According 
to the Supreme Court, the primary inquiry should instead focus on whether the claimed invention 
falls within one of the three fundamental principles exceptions.26 Expanding on this principle as 
the main focus of the case at hand, the Court recognized first that “all inventions at some level 
embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas,” 
                                                          
21 Diehr, 450 U.S. at 191. 
22 Bilski I, 545 F.3d at 954. 
23 Id. (citing Gottschalk v. Benson, 409 U.S. 63, 70 (1972)). 
24 Id. 
25 Bilski, 130 S. Ct. at 3227; see also Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 
F.3d 1347, 1349 (Fed. Cir. 2010). 
26 See Bilski, 130 S. Ct. at 3226. 
and second, “too broad an interpretation of this exclusionary principle could eviscerate patent 
law.”27 The Court began their inquiry by applying “this well-established standard to determine 
whether Myriad's patents claim any ‘new and useful . . . composition of matter,’ . . . or instead 
claim naturally occurring phenomena.”28 
Since 1982, patents claiming isolated gene sequences have cleared this threshold 
inquiry.29  Although these patents were never fully tested in the crucible of litigation until now, 
inventors relied on what they (and their learned counsel) considered the settled expectation of 
patent protection for these discoveries when they invested considerable time and treasure in their 
pursuit. The work and investment of these erstwhile pioneers have led to many important 
discoveries, which have affected not only their fields of research, but many individuals on a very 
personal level, through the realization of diagnosis and treatment of disease. 
To further bolster the relied upon protection, in 2001, USPTO issued Utility Examination 
Guidelines; these guidelines reaffirmed the agency's position that isolated DNA molecules were 
patent eligible.30 In the intervening years, Congress has not indicated that they disagree with the 
PTO's position, which has been inferred as (at the very least) tacit approval. 
                                                          
27 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013) (quoting 
Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1293 (2012)). 
28 Id. 
29 See Eric J. Rogers, Can You Patent Genes? Yes and No, 93 J. PAT. & TRADEMARK OFF. SOC'Y 
19, 19 & n.3 (2010) (citing patents issued March 30 and December 14, 1982); see also STEPHEN 
A. BECKER, PATENT APPLICATIONS HANDBOOK § 4:19 (2010). 
30 Utility Examination Guidelines, 66 Fed. Reg. 1092-1102 (Jan. 5, 2001) (stating that an isolated 
and purified DNA molecule that has the same sequence as a naturally occurring gene is eligible 
for a patent because (1) an excised gene is eligible for a patent as a composition of matter or as 
an article of manufacture because that DNA molecule does not occur in that isolated form in 
nature, or (2) synthetic DNA preparations are eligible for patents because their purified state is 
different from the naturally occurring compound). 
Such was the state of patent law when this case began. Which leaves scholars with the 
pressing question: If the law is to be changed in a manner contrary to the settled expectation of 
the community of inventors, and inventions claiming isolated DNA as their subject matter 
excluded from the broad scope of § 101, should the decision come from Congress or the Court? 
III. Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 
A. Facts of the Case 
This case began with a declaratory judgment action brought to challenge certain claims in 
seven patents related to Myriad’s isolation of the BRCA1 and BRCA2 genes, and the correlation 
between specific mutations in those genes and a heightened risk of developing certain types of 
breast and ovarian cancers.31 Myriad employed many of the pre-eminent scientists in the field of 
genetics and expended vast amounts of time and wealth to isolate the BRCA1 and BRCA2 
genes. The question the Court had to answer is whether this renders the genes patentable?32 
Myriad discovered the precise location and sequence of two human genes, BRCA1 and 
BRCA2, mutations of which can substantially increase the risks of breast and ovarian cancer. 
“The average American woman has a 12- to 13- percent risk of developing breast cancer, but for 
women with certain genetic mutations, the risk can range between 50 and 80 percent for breast 
cancer and between 20 and 50 percent for ovarian cancer.”33 The identification and isolation of 
the BRCA1 and BRCA2 genes allowed Myriad to determine their typical nucleotide sequence.34 
In turn, that information enabled Myriad to develop medical tests that are useful for detecting 
                                                          
31 Myriad, 133 S. Ct. at 2109. 
32 Id. at 2116. 
33 Id. 
34 Technically, there is no “typical” gene because nucleotide sequences vary between individuals, 
sometimes dramatically. Geneticists refer to the most common variations of genes as “wild 
types.” 
mutations in a patient's BRCA1 and BRCA2 genes, thus allowing a physician to assess whether 
the patient had an increased risk of cancer. 
B. Procedural History 
In 2010, Judge Sweet of the U.S. District Court for the Southern District of New York 
invalidated the challenged claims as patent-ineligible under 35 U.S.C. § 101.35 Myriad appealed 
to the U.S. Court of Appeals for the Federal Circuit, which reversed in a divided decision issued 
on July 29, 2011.36 After the Supreme Court issued their decision in Mayo v. Prometheus, they 
granted certiorari, vacated the July 29, 2011 Federal Circuit Myriad decision, and remanded the 
case to the Federal Circuit for reconsideration in view of Mayo.37 Mayo limited the availability 
of patents for medical diagnostic techniques claiming a new way to apply the laws of nature, 
requiring that these techniques recite more than “routine, [or] conventional activity previously 
engaged in by researchers in the field.”38   
The Federal Circuit issued its Myriad remand decision on August 16, 2012, essentially 
reiterating their first decision. Judge Lourie, writing for the majority, emphasized the molecular 
differences between the claimed sequences and the equivalent DNA existing in human cells, 
finding “[i]t is the difference between knowledge of nature and reducing a portion of nature to 
concrete form, the latter activity being what the patent laws seek to encourage and protect.”39  In 
her concurring opinion, Judge Moore focused on the function and utility of the isolated DNA 




38 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1302 (2012). 
39 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 1353 (Fed. 
Cir. 2011), reh'g denied (Sept. 13, 2011), reh'g denied (Sept. 16, 2011), cert. granted, judgment 
vacated sub nom. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 
(2012), and opinion vacated, appeal reinstated, 467 F. App'x 890 (Fed. Cir. 2012). 
sequences, the settled expectations of the inventing community, and her belief that the judiciary 
should defer to Congress on issues where they have acted to determine that the scales had tipped 
in the favor of patentability.40 Contrary, Judge Bryson, in a dissenting opinion., argued that the 
DNA molecules, while structurally different, were not materially different from those found in 
their native environment, therefore rendering them unpatentable.41  
In light of the circuit court holding, the Supreme Court again granted certiorari, 
and heard oral arguments on April 15, 2013.42 
C. The Decision 
 The Court’s decision focuses on the “product of nature” exception to 35 U.S.C. § 101, 
and whether or not the grant of patents on naturally occurring phenomenon would be 
counterproductive to the stated reason for issuing patents: to promote creation.43 The Court’s 
concern was that patents on naturally occurring phenomenon, the basic tools of scientific and 
                                                          
40 Id. at 1367 (Moore, J. concurring) (“Congress has, for centuries, authorized an expansive 
scope of patentable subject matter. Likewise, the United States Patent Office has allowed patents 
on isolated DNA sequences for decades, and, more generally, has allowed patents on purified 
natural products for centuries. There are now thousands of patents with claims to isolated DNA, 
and some unknown (but certainly large) number of patents to purified natural products or 
fragments thereof. . . . I believe we must be particularly wary of expanding the judicial exception 
to patentable subject matter where both settled expectations and extensive property rights are 
involved. Combined with my belief that we should defer to Congress, these settled expectations 
tip the scale in favor of patentability.”). 
41 Id. at 1378 (Bryson, J., dissenting) (“The structural differences between the claimed ‘isolated’ 
genes and the corresponding portion of the native genes are irrelevant to the claim limitations, to 
the functioning of the genes, and to their utility in their isolated form.“). 
42 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2114 (2013). 
43 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
technological work, would “tie up” the use of such tools and thereby “inhibit future innovation 
premised upon them.”44  
 1. Naturally Occurring DNA, Even Though Isolated, Is Not Patentable 
 The Court recognized that Myriad “found an important and useful gene” but then 
stipulated that “separating that gene from its surrounding genetic material is not an act of 
invention.”45 The Court relied heavily on three prior decisions in their holding: Diamond v. 
Chakrabarty; Funk Brothers Seed Co. v. Kalo Inoculant Co.; and Mayo Collaborative Services v. 
Prometheus Laboratories, Inc. Each case involved the use or interpretation of a natural 
phenomenon, with differing levels of modification or intervention affecting each outcome.  
Chakrabarty patented the genetic modification of a bacterium making it “capable of 
breaking down multiple components of crude oil.”46 Funk Brothers Seed Co. distilled six 
different Rhizobium bacteria and combined them into a powder form that could inoculate the 
seeds of certain legumes, which enabled them “to take nitrogen from the air and fix it in the plant 
for conversion to organic nitrogenous compounds.”47 Finally, Prometheus Laboratories, Inc. 
determined the “relationships between concentrations of certain metabolites in the blood and the 
likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.”48 This 
allowed them to define a process by which health care professionals could test their patients in 
order to determine the correct dosage without trial and error, thus reducing the risks associated 
                                                          
44 Myriad, 133 S. Ct. at 2116 (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. 
Ct. 1289, 1293 (2012)). 
45 Id. at 2117. 
46 Chakrabarty, 447 U.S. at 305. 
47 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 128 (1948). 
48 Mayo, 132 S. Ct. at 1296. 
with the drug.49 In each case, a natural phenomenon or process was significantly improved 
and/or combined to enhance usability, however, the Court found they were not all patent-eligible.  
a) Diamond v. Chakrabarty 
In 1972, Ananda Mohan Chakrabarty, working with the General Electric Corporation, 
developed a new strain of bacterium that could degrade multiple components of crude oil, 
thereby speeding up the process of decomposition. Naturally occurring bacteria that could 
accomplish the same process were known, however, no known bacterium was capable of 
breaking down multiple components of the crude oil complex.50 
For example, at the time of invention, biological control of oil spills required the use of a 
mixture of naturally occurring bacteria, each capable of degrading one component of the oil 
complex.51 As part of this degradation process, oil is broken down into simpler substances that 
serve as food for aquatic life. However, for various reasons, only a portion of any such mixed 
culture survives to attack the oil spill.52 Conversely, Chakrabarty's micro-organism promised a 
                                                          
49 Id. 
50 Chakrabarty, 447 U.S. at 305. 
51 See id. at 305 n.2; see also U.S. Patent No. 3,813,316 col. 5 ll. 9-16 (filed Jun. 7, 1972). 
52 ‘316 Patent col. 5 ll. 9-33. Microbial strains are known that can decompose individual 
components of crude oil (thus, various yeasts can degrade aliphatic straight-chain hydrocarbons, 
but not most of the aromatic and polynuclear hydrocarbons). Pseudomonas and other bacteria 
species are known to degrade the aliphatic, aromatic and polynuclear aromatic hydrocarbon 
compounds, but, unfortunately any given strain can degrade only a particular component. For 
this reason, prior to the instant invention, biological control of oil spills had involved the use of a 
mixture of bacterial strains, each capable of degrading a single component of the oil complex on 
the theory that the cumulative degradative actions would consume the oil and convert it to cell 
mass. This cell mass in turn serves as food for aquatic life. However, since bacterial strains differ 
from one another in (a) their rates of growth on the various hydrocarbon components, (b) 
nutritional requirements, production of antibiotics or other toxic material, and (c) requisite pH, 
temperature and mineral salts, the use of a mixed culture leads to the ultimate survival of but a 
portion of the initial collection of bacterial strains. As a result, when a mixed culture of 
rapid and more efficient oil-spill control by breaking down multiple components of oil with a 
much higher survival rate.53 
The Supreme Court held the micro-organism to be patentable, recognizing that what 
Chakrabarty produced was a “new bacterium with markedly different characteristics from any 
found in nature and one having the potential for significant utility.”54 In the case at hand, the 
Court distinguished Myriad by pointing out that Myriad had not created anything. They had 
instead merely isolated an existing natural phenomenon. Where Chakrabarty had added plasmids 
in order to “create” a new bacterium with greatly improved “capacity for degrading oil,”55 by 
contrast, “Myriad did not create anything. To be sure, it found an important and useful gene, but 
separating that gene from its surrounding genetic material is not an act of invention.”56  
b) Funk Brothers Seed Co. v. Kalo Inoculant Co. 
Funk Brothers Seed Co. combined six different naturally occurring rhizobium bacteria 
that infect the roots of legumes, enhancing the plant’s ability “to take nitrogen from the air and 
fix it in the plant for conversion to organic nitrogenous compounds.”57 The bacteria occurred 
naturally and performed essentially the same function as Mother Nature.58 However, the 
different species of bacteria only combined with specific plants.59 In addition, when certain 
strains came in contact with one another they inhibited the efficacy of each other, greatly 
                                                                                                                                                                                           
hydrocarbon-degrading bacteria are deposited on an oil spill the bulk of the oil often remains 
unattacked for a long period of time (weeks) and is free to spread or sink. 
53 Id., at col. 3 l. 5-19. 
54 Chakrabarty, 447 U.S. at 310. 
55 Id. at 305. 
56 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2117 (2013). 
57 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 128 (1948). 
58 U.S. Patent No. 2,200,532 col. 1 ll. 5-8. 
59 Funk Bros., 333 U.S. at 129; see also ‘532 Patent col. 2 ll. 31-36. 
reducing nitrogen fixation.60 Funk Brothers Seed Co. determined that there were six strains that 
could inoculate many different types of legumes, without exhibiting the mutually inhibitory 
behavior.61 Consequently, Funk Brothers combined the six different types of bacteria packaged 
in powder form, allowing farmers to infect the seeds of their varied legume crops without worry 
of cross inoculation, which would cancel out the beneficial effects.62 
The focus of Funk Brothers work was not to create a new strain of the bacterium; instead, 
their work concentrated on the identification of different bacterium that would not inhibit the 
beneficial effects of each other and would inoculate a large number of legume varieties. 
Therefore, farmers would be able to purchase one inoculation product, without having to worry 
about cross inoculation. This work was ground breaking in the field; however, the Supreme 
Court held that it was not patentable.63 The Court held that they had not created something new, 
but had instead mixed what nature had created into a very useful combination.64 
In the instant case, the Supreme Court held that Myriad was analogous to Funk Brothers. 
The Court found that Myriad had not created something new; instead, they had taken naturally 
                                                          
60 See Funk Bros., 333 U.S. at 129-30 (“[T]he different species of the Rhizobia bacteria produced 
an inhibitory effect on each other when mixed in a common base, with the result that their 
efficiency was reduced.”) 
61 See id. at 130 (“[Funk Brothers] discovered that there are strains of each species of root-nodule 
bacteria which do not exert a mutually inhibitive effect on each other. [They] also ascertained 
that those mutually non-inhibitive strains can, by certain methods of selection and testing, be 
isolated and used in mixed cultures. Thus [they] provided a mixed culture of Rhizobia capable of 
inoculating the seeds of plants belonging to several cross-inoculation groups.”) 
62 See id. 
63 See id. at 131 (Douglas, J) (“[H]owever ingenious the discovery of that natural principle may 
have been, the application of it is hardly more than an advance in the packaging of the 
inoculants.”). 
64 See id. at 132 (“The application of this newly-discovered natural principle to the problem of 
packaging of inoculants may well have been an important commercial advance. But once nature's 
secret of the non-inhibitive quality of certain strains of the species of Rhizobium was discovered, 
the state of the art made the production of a mixed inoculant a simple step. Even though it may 
have been the product of skill, it certainly was not the product of invention.”) 
occurring phenomenon and distilled them into an admittedly advantageous combination.65 The 
Myriad Court emphasized that “[g]roundbreaking, innovative, or even brilliant discovery does 
not by itself satisfy the § 101 inquiry,”66 nor does “extensive effort.”67 
3. Mayo Collaborative Services v. Prometheus Laboratories, Inc. 
 Prometheus Labs sued the Mayo Clinic after learning that they had developed testing 
procedures that infringed U.S. Patents 6,355,623 and 6,680,302. These patents claimed steps of 
testing blood samples that allowed physicians to determine the proper dosage for thiopurine drug 
treatment of immune-mediated diseases, such as Crohn’s disease and Ulcerative Colitis.68  When 
ingested, the body converts the thiopurine into therapeutic metabolites that suppress the patient’s 
immune system and alleviate symptoms.69 The patented test provided a means to measure the 
level of two such metabolites in the blood: 6-thioguinine and 6-methylmercaptopurine.70 
According to the patent, metabolite levels “greater than about 400” and “greater than about 
7000” respectively, indicate that an adjustment in drug dosage may be required  to avoid toxic 
side effects.71 
After purchasing and using the Prometheus test from 1999-2004, the Mayo Clinic 
developed their own test utilizing similar methods, however, they used different determinative 
                                                          
65 Funk Bros., 333 U.S. at 128. 
66 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2117 (2013). 
67 Id. at 2118. 
68 U.S. Patent No. 6,355,623 col. 2 ll. 16-41 (filed Apr. 8, 1999); U.S. Patent No. 6,680,302 col. 
2 ll. 18-43 (filed Dec. 27, 2001). 
69 ‘623 Patent col. 8 ll. 9-20. 
70 Id. 
71 Id. 
metabolite levels that they claimed were more effective.72 Mayo announced their intention to 
begin using the test in their clinics, as well as offering it for sale to other potential users.73 
Prometheus then filed suit, and Mayo subsequently rescinded the announced deployment of their 
test pending the outcome of litigation. A federal judge for the Southern District of California 
granted summary judgment in favor of Mayo. The judgment held that although Mayo was 
infringing the patents, the metabolites “6-TG and 6-MMP are products of the natural 
metabolizing of thiopurine drugs, and the inventors merely discovered the relationship between 
these naturally produced metabolites and therapeutic efficacy and toxicity,” therefore the patents 
were invalid and unenforceable.74  
Prometheus appealed, and the U.S. Court of Appeals for the Federal Circuit reversed the 
lower court order.75 The Federal Circuit held that the lower court erred in categorizing the 
administrative and determinative steps as data gathering steps.76 Conversely, the court held that 
the administering and determining steps in the patents were part of the treatment regimes for 
various diseases using thiopurine drugs. Therefore, the claims were “not drawn merely to 
correlations between metabolite levels and toxicity or efficacy.”77 In addition, the court held that 
while mental steps are not normally patentable, the mental steps in the Prometheus Patents were 
subsequent steps that made use of the data provided by the prior administering and determining 
                                                          
72 Prometheus Labs., Inc. v. Mayo Collaborative Servs., CIV. 04CV1200JAHRBB, 2008 WL 
878910 (S.D. Cal. Mar. 28, 2008) rev'd, 581 F.3d 1336 (Fed. Cir. 2009) cert. granted, judgment 




75 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 1339 (Fed. Cir. 2009) 
cert. granted, judgment vacated, 130 S. Ct. 3543 (2010) (reversing because the district court 
erred as a matter of law in finding the asserted claims to be drawn to nonstatutory subject matter) 
76 Id. 
77 Id. at 1348. 
steps.78 Therefore, the “addition of the mental steps to the claimed methods thus does not remove 
the prior two steps from that realm.”79  
Mayo appealed to the Supreme Court who granted certiorari and vacated the Federal 
Circuit opinion, remanding the case for review in light of Supreme Court’s 2010 decision in 
Bilski v. Kappos, which held that a key legal test utilized in the federal circuit decision, the 
“machine-or-transformation test,”80 was not the sole test for deciding whether a process was 
patent-eligible.81 The Federal Circuit once again considered the case and came to the same 
conclusion they had previously, emphasizing that the Supreme Court had not invalidated the 
machine-or-transformation test, but rather that they had held that it was not the sole test. 
Mayo once again appealed and the Supreme Court granted certiorari, and once again 
reversed the Federal Circuit Court decision, holding that the claimed processes were not novel, 
but “involve well-understood, routine, conventional activity previously utilized by researchers in 
the field.”82 Further, they held that “upholding the patents would risk disproportionately tying up 
the use of the underlying natural laws, inhibiting their use in the making of further 
discoveries.”83 The emphasis on preemption as a reason for invalidation of patent claims is the 
key to understanding the importance of the Mayo decision in the current litigation.  
                                                          
78 Id. 
79 Id. 
80 The “machine-or-transformation test” is a two-branched inquiry; an applicant may show that a 
process claim satisfies § 101 either by showing (1) that his claim is tied to a particular machine, 
or (2) by showing that his claim transforms an article. In re Bilski (Bilski I), 545 F.3d 943, 950 
(Fed. Cir. 2008), aff'd but criticized sub nom. Bilski v. Kappos, 130 S. Ct. 3218 (2010). 
81 Bilski, 130 S. Ct. at 3227. 
82 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1294 (2012). 
83 Id. 
Justice Thomas, in this remarkably restrained opinion, chose not to highlight preemption 
as the reason for the Court’s holding. However, the opinion does reveal that the dangers of 
preemption were at least part of the Court’s reason for holding the isolated DNA claims invalid. 
Citing Mayo, the Court reasoned that without the product of nature exception, “there would be 
considerable danger that the grant of patents would ‘tie up’ the use of such tools and thereby 
‘inhibit future innovation premised upon them.’”84  
In addition, Justice Thomas, contemplating the possible ways that Myriad could have 
couched the discovery in patentable terms, postulated that had Myriad patented the chemical 
compound of the gene as a unique molecule instead of the naturally occurring gene sequence, 
then a would be infringer “could arguably avoid at least Myriad's patent claims on entire 
genes . . . by isolating a DNA sequence that included both the BRCA1 or BRCA2 gene and one 
additional nucleotide pair.”85 This obviously was not the case here, but Justice Thomas’ 
reasoning illustrated the dangers against which preemption seeks to protect, tying up a natural 
phenomenon such that others could not build on the work of the patentee. Or, put another way, 
Myriad’s claims monopolized what should be “free to all men and exclusively reserved to 
none.”86 
2. Summary of the Court’s Reasoning 
 The Court was not swayed by Myriad’s argument that similar to the bacterium in 
Chakrabarty, Myriad’s “claims are drawn to man-made compositions of matter (or at least man-
                                                          
84 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013) (quoting 
Mayo, 132 S. Ct. at 1301). 
85 Id. at 2118. 
86 Funk Bros., 333 U.S. at 130. 
made improvements thereof).”87 The Court literally held quite the opposite when it stated: 
“Myriad did not create anything. To be sure, [Myriad] found an important and useful gene, but 
separating that gene from its surrounding genetic material is not an act of invention.”88 
The Court found that Myriad’s isolated DNA claims were analogous to those in Funk 
Brothers; they had taken naturally occurring phenomenon and distilled them into an admittedly 
advantageous combination.89 And like the claims in Funk Brothers, the Court invalidated 
Myriad’s claims citing the law of nature exception.90 The Court emphasized that 
“[g]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the § 101 
inquiry,”91 nor does “extensive effort.”92 
Finally, the Court made a subtle nod to the proverbial bastard child of patent law: 
preemption. While enumerating the reasoning for the long held implicit law of nature exception, 
Justice Thomas reasoned that “without [the law of nature] exception, there would be 
considerable danger that the grant of patents would ‘tie up’ the use of such tools and thereby 
‘inhibit future innovation premised upon them.’ ”93 
                                                          
87 Brief for Respondents at 34, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-
398 (U.S. Mar. 7, 2013), 2013 WL 860315. 
88 Myriad, 133 S. Ct. at 2117. 
89 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 128 (1948). 
90 Myriad, 133 S. Ct. at 2117 (“[Funk Brothers] patent claim . . . fell squarely within the law of 
nature exception. So do Myriad's. Myriad found the location of the BRCA1 and BRCA2 genes, 
but that discovery, by itself, does not render the BRCA genes “new . . . composition[s] of 
matter,” § 101, that are patent eligible.”) 
91 Id. 
92 Id. at 2118. 
93 Id. at 2116 (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1301 
(2012)).  
Taken as a whole, the Court leaves us with the fungible guidance that in order to be 
patent-eligible natural material must be altered by the inventor “in any way.”94 The attempts by 
the patenting community to define and understand this “in any way” standard, will be hotly 
contested, both in and out of courts of law, for years to come. 
IV. Impact of the Holding Moving Forward 
 The decision affects three distinct groups of inventors, in very different ways. These 
groups are: those holding current patents which may now claim patent-ineligible matter, those 
who have current applications pending with similar claims, and those who are in the various 
stages of Research and Development in anticipation of patent filing. The following will be a brief 
discussion of the impact on each group. 
A. Current Patent Holders 
 First, the group that will be impacted the most are those who currently hold patents 
claiming isolated genes. The claims contained in these patents that cover isolated DNA can now 
be invalidated, which will impact the inventors or patent holders in various ways. First, if the 
patented material is licensed, the licensees, who will no longer be protected by the patent in their 
own endeavors, will look for ways to terminate the license. This could be accomplished utilizing 
existing contractual terms, or in some cases, by patent challenges by the licensee themselves who 
seek to invalidate the patent claims so they can practice the subject matter free from the 
constraints of the license.95 Second, inventors who practice the inventions claimed in the patents 
                                                          
94 Id. at 2117 (summarizing the Funk Brothers holding, “that the composition was not patent 
eligible because the patent holder did not alter the bacteria in any way”). 
95 Article III of the Constitution requires that a case-or-controversy exist before a suit may be 
brought in federal court. This so called “federal standing doctrine” imposes three limitations on 
prospective plaintiffs. First, the plaintiff must have suffered an injury in fact - an invasion of a 
themselves will likely see competitors seeking invalidation,96 or, more likely, their competitors 
will simply begin to practice the claimed inventions, thus leaving the inventors in the unenviable 
position of deciding whether to initiate an infringement suit. However, given the cost and time-
consuming nature of patent litigation, patent holders are more likely not to file suit over now 
questionable claims. 
 On the other side, there are likely many patents that contain broad claims that encompass 
both unpatentable material (isolated DNA), as well as patent eligible material (cDNA). Going 
forward these will be the most interesting cases. Patentees will most likely choose to take 
proactive steps to shore up their patent coverage by applying for reissuance of the patent. 35 
U.S.C. § 251 governs the reissue of patents and outlines the rules USPTO will follow when 
deciding whether or not to grant a reissued patent. Section 251 provides that the USPTO may 
reissue a patent, upon surrender of the original patent, if the patent is “through error,97 deemed 
                                                                                                                                                                                           
legally protected interest which is (a) concrete and particularized, and (b) actual or imminent, not 
conjectural or hypothetical. Second, there must be a causal connection between the injury and the 
conduct complained of-the injury has to be fairly traceable to the challenged action of the 
defendant.  Third, it must be likely, as opposed to merely speculative, that the injury will be 
redressed by a favorable decision. If a plaintiff fails to satisfy any of these requirements, they 
cannot sue in federal court. In the patent context, that means they cannot challenge the validity of 
a patent. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1342-43 (Fed. Cir. 2011), reh'g denied (Sept. 13, 2011), reh'g denied (Sept. 16, 2011), cert. 
granted, judgment vacated sub nom. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 
132 S. Ct. 1794 (2012), opinion vacated, appeal reinstated, 467 F. App'x 890 (Fed. Cir. 2012). It 
is likely that a licensee will have little trouble meeting this burden; however, this may be more 
relevant to patentee’s competitors discussed infra. 
96 Competitors may have more trouble initially meeting the limitations of the federal standing 
doctrine, but the inclusion of the word imminent threat of invasion of a legally protected interest 
will likely get many would be plaintiffs into court. See supra note 74. 
97 Ball Corp. v. United States, 729 F.2d 1429, 1435-36 (Fed. Cir. 1984) (holding, for reissue 
purposes, that “error is established where there is no evidence that the appellant intentionally 
omitted or abandoned the claimed subject matter”). 
wholly or partly inoperative or invalid.”98 Section 251 is remedial in nature, based on 
“fundamental principles of equity and fairness, and should be construed liberally;” nonetheless, 
“not every event or circumstance that might be labeled ‘error’ is correctable by reissue.”99 
Patentees with claims that are now overly broad fall into this reissue category and may be 
allowed, within limitations, to amend their claims to remove the patent-ineligible material while 
retaining the patentable subject matter.100 
Section 251 limits the subject matter of the amended claims to subject matter that was in 
the original patent stating: “no new matter shall be introduced into the application for reissue.”101 
Careful claim drafting, designed to give the maximum coverage possible under the new 
guidelines, is where the need for an excellent patent lawyer comes into play. Introduction of new 
matter does not mean that the substitute claim can only contain the same subject matter as the 
original. Instead, it means that it cannot contain subject matter that was not included in the 
original claims and/or specifications.102 Therefore, taking into account the broad nature of patent 
specifications, a good patent drafter may be able to retain much of the originally covered 
material by crafting claims utilizing the original specifications and subject matter that the Court 
                                                          
98 35 U.S.C. § 251 (2006) (pre-AIA) (applicable to patents issued before Sep. 16, 2012); see also 
35 U.S.C. § 251 (2012) (applicable to patents issued on or after Sep. 16, 2012). The post-
America Invents Act section omits “without any deceptive intention.”  Leahy-Smith America 
Invents Act § 20, Pub. L. No. 112-39, 125 Stat. 284, 333 (2011). 
99 In re Weiler, 790 F.2d 1576, 1579 (Fed. Cir. 1986). 
100 Henkel Corp. v. Coral, Inc., 754 F. Supp. 1280, 1294 (N.D. Ill. 1990), aff'd, 945 F.2d 416 
(Fed. Cir. 1991) (“A reissue application prosecution is a corrective proceeding, with one of the 
express purposes being to reduce the scope of an overclaimed invention—to correct the 
overbreadth.”); see also White v. Fafnir Bearing Co., 389 F.2d 750, 754-55 (2d Cir. 1968) 
(“[T]he purpose of the reissue patent provision is to permit an inventor to correct a mistake when 
his patent application covers more than the true invention.”) 
101 Id. 
102 See In re Rosuvastatin Calcium Patent Litig., 703 F.3d 511, 526 (Fed. Cir. 2012) (holding that 
the decision to claim a specific chemical compound in the reissue application was proper because 
it “was explicitly described in the [patent] specification as the preferred compound”). 
did not exclude from patentability, i.e. chemical compositions of the isolated DNA sequence,103 
emphasizing the importance the claimed cDNA,104 claiming the methods of isolation,105 or, if 
applicable, claiming the DNA in an altered state.106  
While this decision might affect those holding one of the estimated 40,000 genetic 
material patents, it will certainly impact those who hold one of the almost 3,000 which are 
specifically directed to isolated DNA molecules.107 The effects may be minimized by clear, 
unbiased, and unvarnished assessment of the continued utility of existing patents. If they are 
worth saving, a well thought out, and progressive looking plan of action to recapture as much 
protection as possible will be necessary. 
  
                                                          
103 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2118 (2013).  
Justice Thomas intimated that, had Myriad’s claims been expressed in terms of chemical 
composition, they may have survived the product-of-nature exclusion. “Myriad's claims are 
simply not expressed in terms of chemical composition, nor do they rely in any way on the 
chemical changes that result from the isolation of a particular section of DNA.”  Id. 
104 Id. at 2119 (“cDNA is not a ‘product of nature’ and is patent eligible under § 101, except 
insofar as very short series of DNA may have no intervening introns to remove when creating 
cDNA.”) 
105 Id. (“[T]here are no method claims before this Court. Had Myriad created an innovative 
method of manipulating genes while searching for the BRCA1 and BRCA2 genes, it could 
possibly have sought a method patent.”) 
106 Id. at 2120 (holding that DNA may be patentable if “the order of the naturally occurring 
nucleotides has been altered. Scientific alteration of the genetic code presents a different inquiry, 
and we express no opinion about the application of § 101 to such endeavors.”) 
107 See Rogers, supra note 29, at 19, 40; see also Richard Wolf, Justices Rule Human Genes 
Cannot Be Patented, USA TODAY, (Jun. 13, 2013), http://www.usatoday.com/story/news/nation/ 
2013/06/13/supreme-court-gene-breast-ovarian-cancer-patent/2382053/ (“Since 1984, the U.S. 
Patent and Trademark Office has granted more than 40,000 patents tied to genetic material.”); 
see also Randolph V. Clower, Impending Myriad Decision Portends Promethean Consequences 
for Biotech Industry, METROPOLITAN CORP. COUNS., Mar. 2013, at 9. 
B. Patent Applications in their Various Stages and Inventors Anticipating Patent 
Applications 
Existing patent applications and inventors who are in various stages of Research and 
Development (R&D) anticipating application for patent protection will take a similar approach, 
albeit through a different route. Pending applications will need to be amended to remove patent-
ineligible subject matter, while future applications will need to be crafted to avoid their 
inclusion. However, those with current applications pending will first need to decide if they wish 
to continue the current prosecution, in which they will not be allowed to include new subject 
matter in claim amendment;108 or, to withdraw the application, regroup, and reassess their plan 
of attack. 
C. Continued Patentability of Gene Isolation Methods 
It is important to note that this decision does not affect the patentability of the methods 
utilized to isolate the DNA.109 Statute defines claimed inventions that fall into the process 
category as: a “process, art or method, and includes a new use of a known process, machine 
manufacture, composition of matter, or material.”110 The Supreme Court further explained: 
                                                          
108 35 U.S.C. § 132(a) (2012) (“Whenever, on examination, any claim for a patent is rejected, or 
any objection or requirement made, the Director shall notify the applicant thereof, stating the 
reasons for such rejection, or objection or requirement, together with such information and 
references as may be useful in judging of the propriety of continuing the prosecution of his 
application; and if after receiving such notice, the applicant persists in his claim for a patent, with 
or without amendment, the application shall be reexamined. No amendment shall introduce new 
matter into the disclosure of the invention.”). 
109 Myriad, 133 S. Ct. at 2119 (“Had Myriad created an innovative method of manipulating genes 
while searching for the BRCA1 and BRCA2 genes, it could possibly have sought a method 
patent.”) 
110 35 U.S.C. § 100(b) (2012). 
A process is a mode of treatment of certain materials to produce a given result. It 
is an act, or a series of acts, performed upon the subject-matter to be transformed 
and reduced to a different state or thing. If new and useful, it is just as patentable 
as is a piece of machinery. In the language of the patent law, it is an art. The 
machinery pointed out as suitable to perform the process may or may not be new 
or patentable; whilst the process itself may be altogether new, and produce an 
entirely new result. The process requires that certain things should be done with 
certain substances, and in a certain order; but the tools to be used in doing this 
may be of secondary consequence.111 
Thus, the Court left the door open to patent the methods or processes used to isolate the DNA. 
The reasoning behind this distinction once again returns to preemption. The patentability of the 
method and/or process of isolation does not preclude others from using the isolated gene, it 
simply limits the way in which they can accomplish the isolation of the desired gene. In light of 
this distinction, the methods for isolating the DNA and, more importantly, new applications of 
knowledge gleaned from the information obtained from the genetic sequences, remain patent-
eligible. 
D. Overall Effect on Innovation and Industry 
 The decision, while far reaching in its implication, may not have the chilling effect that 
many in the legal profession predicted.112 Biomedical researchers, especially those at universities 
and government funded facilities, report that intellectual property concerns have very little, if 
any, impact on their research.113 In a 2003 survey, Walsh et al. found that of the participants in 
                                                          
111 Diamond v. Diehr, 450 U.S. 175, 182-83 (1981) (internal quotations omitted). 
112 See Dalila Argaez Wendlandt & James F. Haley, Jr., Supreme Court Rules That Isolated 
Human Gene Is Not Patent Eligible in AMP v. Myriad, ROPES & GRAY ALERT (Jun. 14, 2013), 
http://www.ropesgray.com/news-and-insights/Insights/2013/06/~/media/Files/alerts/2013/06/20 
130614_IP_Alert.ashx; see also Clower, supra note 106, at 9. 
113 John P. Walsh, Ashish Arora & Wesley M. Cohen, Working Through the Patent Problem, 
299 SCIENCE 1021, 1021 (Feb. 14, 2003) (“[M]ost respondents said that infringement of research 
tool patents, especially by university researchers, is common. A third of the industrial 
the study “almost none of [the] respondents reported worthwhile projects being stopped because 
of issues of access to IP rights to research tools.”114 This seems to be in large part because 
researchers choose to ignore patents, making infringement common.115 When those who had 
knowingly infringed a patent were asked why they chose to ignore the patentee’s rights most 
“justified such infringement by invoking a research exemption.”116 
 On the other hand, human genetics researchers, for whom gene patents are obviously 
particularly relevant, will likely be the ones most impacted by the decision. Unlike the 
biomedical researchers in the Walsh et al. surveys, a survey by Cho et al. of U.S. clinical 
genetics laboratories indicated that 65% had received notification of potential infringement.117 
                                                                                                                                                                                           
respondents (and all nine university or government lab respondents) acknowledged occasionally 
using patented research tools without a license.”) 
114 Id. 
115 Id. 
116 Id. (Internal quotations omitted). This study was largely completed before the Madey v. Duke 
decision in which the U.S. Court of Appeals for the Federal Circuit held that educational 
institutions were not automatically exempt from infringement suits because they are not-for-
profit, or the use of the patented material had no commercial application. 307 F.3d 1351, 1362 
(Fed. Cir. 2002). Instead, they clarified previous holdings by specifying that a courts focus 
should be “on the legitimate business [the accused infringer] is involved in and whether or not 
the use [of the patented technology] was solely for amusement, to satisfy idle curiosity, or for 
strictly philosophical inquiry.” Id. In response to this holding, Walsh et al. conducted another, 
similar study in 2005 to determine the impact of the decision on researchers’ practices. 
Interestingly, the holding, while most were aware of it, had little impact on a similar set of 
subjects. Only 2% (i.e., eight) of the participants report having begun checking for patents in the 
two years since Madey v. Duke, which suggests little impact of the decision. Five percent had 
been made aware of intellectual property (IP) relevant to their research through a notification 
letter sent either to them or their institution, which differs little from the 3% who reported having 
received such notification five years ago (prior to the Madey v. Duke decision). Furthermore, 
although 22% of respondents report being notified by their institutions to respect patent rights 
(versus 15% in the earlier study), such notification did not appreciably affect the likelihood of 
checking for patents - 5.9% of those receiving such instruction checked for patents versus 4.5% 
of those not receiving instruction. John P. Walsh, Charlene Cho & Wesley M. Cohen, View from 
the Bench: Patents and Material Transfers, 309 SCIENCE 2002, 2002-03 (Sept. 29, 2005). 
117 Mildred K. Cho, Samantha Illangasekare, Meredith A. Weaver, Debra G. B. Leonard & Jon 
F. Merz, Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services, 5 
These are the labs that conduct important research to develop clinical tests. The Cho et al. study 
found that 25% of those labs had discontinued a test and 53% decided not to conduct research to 
develop a test because of the threat of patent litigation. Further, 67% felt that patents inhibited 
their ability to conduct genetic research and 85% indicated that patents resulted in less sharing of 
information among researchers.118 Similarly, an opinion poll conducted by Dr. Isaac Rabino, a 
professor of Biological and Health Sciences at Empire State College, of the members of the 
American Society of Human Genetics, revealed that 49% of respondents reported that patents 
delayed or limited their research.119 To the extent that such research was inhibited by the 
existence of a patent on a DNA sequence, the removal of that barrier could prove significant. 
 So with the door open and researchers ready to innovate, the burning question becomes  
whether anyone will pay to keep the lights on, the equipment working, and oh yes,, the 
researchers paid? In a perfect world, we wouldn’t have to worry about the cost of research. Ideas 
could be developed to their fullest potential, free from monetary and time constraints, and ideas 
would be shared by all people who would collaborate freely. Alas, this Utopian vision does not 
exist and innovators cannot live on ideas alone. So where is the money coming from, and will it 
continue without the promise of patent protection? 
Researchers are likely to be funded by a mix of grants from various government agencies, 
institutions, and foundations. For example, a 2007 study of the movement of carbon in the ocean 
was funded by the National Science Foundation, the U.S. Department of Energy, the Australian 
                                                                                                                                                                                           
J. MOLECULAR DIAGNOSTICS 3, 5 (2003), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907 
368/pdf/0108.pdf. 
118 Id. 
119 Isaac Rabino, How Human Geneticists in US View Commercialization of the Human Genome 
Project, 29 NATURE GENETICS 15, 16 (2001). 
Cooperative Research Centre, and the Australian Antarctic Division.120  Other research is funded 
by private companies who generally finance research projects or studies related to their field. 
This type of finding is prevalent is some fields, especially medicine. In the U.S., almost 75% of 
clinical trials in medicine are paid for by private companies.121 
V. cDNA Is Patent-Eligible! But Is It Patentable? 
 An overly simplified description of the difference between naturally occurring DNA and 
cDNA is that DNA contains the instructions for building every protein the body utilizes,122 as 
well as many unused (non-coding),123 or inactive segments.124 Synthetic DNA (aka cDNA), is 
made in a lab by transcribing mRNA (which is an inverse copy of the original DNA), into a 
complementary form (an inverse copy of the mRNA), which contains the same essential code as 
its naturally occurring compliment (DNA) with the unused segments excluded.125 
 So what makes the cDNA patent-eligible? The answer is: the hands of man! In 1799, 
Chief Justice Lord Kenyon penned the infamous gold-standard for determining the threshold 
question of patentability, “I have no doubt in saying, that this is a patent for a manufacture, 
which I understand to be something made by the hands of man.”126 A similar sentiment, quoted 
with approval by the Supreme Court in Chakrabarty and often preached as the will of Congress, 
                                                          
120 Ken O. Buesseler et al., Revisiting Carbon Flux Through the Ocean's Twilight Zone, 316 
SCIENCE 567 (Apr. 27, 2007). 
121 Thomas Bodenheimer, Uneasy Alliance: Clinical Investigators and the Pharmaceutical 
Industry, 342 NEW ENG. J. MED. 1539 (2000). 
122 BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 104 (4th ed. 2002). 
123 Id. at 341. 
124 Id. at 401. 
125 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013). 
126 Hornblower v. Boulton (K.B. 1799), 8 T.R. 95, 98-99 (emphasis added). 
that patentable subject matter should “‘include anything under the sun that is made by man.’”127 
And once again in this case, the Supreme Court dismissed the naturally occurring nucleotide 
sequence necessary to make the invention useful,128 finding instead that “the lab technician 
unquestionably creates something new when cDNA is made.”129 
 The continued patent-eligibility of cDNA has been hailed by many as a win for the 
biotech industry.130 The reason most often cited being that commercially, cDNA may be the 
most important form of DNA used.131 While this may be true, this is a truly shortsighted view. 
Just because cDNA meets the threshold requirements of § 101, does not mean that it is 
patentable, or that existing patents will withstand an invalidity action. The Court merely held that 
cDNA is eligible to walk through the door; it must still survive the gauntlet that awaits once 
inside. 
 To highlight this point, let’s take a hypothetical cDNA molecule. The Court points out 
that cDNA does not contain introns like the naturally occurring DNA it compliments, 
incidentally one of the reasons they held it is not a “product of nature.”132 mRNA is a more 
useful predictor of a polypeptide sequence than DNA because the introns have been spliced out, 
                                                          
127 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (citing S. REP. NO. 1979, 82d Cong., at 5 
(1952); H.R. REP. NO. 1923, 82d Cong., 2d Sess., at 6 (1952)). 
128 Myriad, 133 S. Ct. at 2119. 
129 Id. 
130 Jeffrey M. Perkel, Gene Patents Decision: Everybody Wins, Scientist (Jun. 18, 2103), 
http://www.the-scientist.com/?articles.view/articleNo/36076/title/Gene-Patents-Decision--
Everybody-Wins/ (“Last week’s Supreme Court decision to invalidate patents on human genes 
was a win for patients, independent researchers, and even the wider biotech industry.”). 
131 Magdalina Gugucheva, Genewatch: The Physical Embodiment of Information, COUNCIL FOR 
RESPONSIBLE GENETICS, http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatch 
Page.aspx?pageId=302 (“Currently, any commercial diagnostic test must use cDNA. Isolated 
DNA in its natural form is not usable for these purposes. Furthermore, any research into the 
BRCA1/2 genes requires the use of cDNAs.”). 
132 Id. 
however, it is not as stable because it’s single stranded structure make it more prone to undesired 
chemical reactions. Enter cDNA, an inverse, double stranded copy of the mRNA that is more 
stable.133 
This is all sounding very exciting if I am a researcher. I found the gene I want to study, I 
identified the mRNA transcript and now I can make cDNA. I know I can’t get patent protection 
for all the work I put into discovering the gene sequence, but the Supreme Court did say that I 
could patent the more useful cDNA. Awesome, where is the patent application? But, and there is 
a big but, isn’t it logical to remove the non-coding portions? They don’t do anything anyway. 
How about making more stable copies of a useful molecule; that sounds obvious too, right? 
Therein lies the problem. Compliments of naturally occurring DNA are not novel, nor are they 
non-obvious. If you want to work with most genes, then cDNA is going to be one of the obvious 
tools you use. So even though the very useful tool you just created has been called patent-eligible 
by the Supreme Court, the hypothetical person of ordinary skill in the art is going to keep you 
from reaching the end of the gauntlet, and your discovery remains unpatentable. 
Obviously this was a rather ridiculous, and probably not very realistic scenario, but it 
does serve to highlight the problem with all the rhetoric and misinformation. The Supreme Court 
did not hold that you will get a patent for the cDNA you created, or the DNA you described as a 
chemical compound instead of the natural sequence, or the methods you used to discover such. 
The Court only addressed the question of whether or not they were patent-eligible material. To 
actually be patented, the invention must meet the other requirements of Title 35 as well. 
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VI. Conclusion 
Where does this decision leave the patenting community? Unfortunately, lamenting as 
Paul, “[f]or now we see through a glass, darkly.”134 The decision, despite all the buildup, has 
given the inventing community few answers, and perhaps even more questions. Perhaps Myriad 
summed it up best in a post on their Facebook page saying the case was about more than patent 
claims: “It was about human health, and innovation to make sure that cancer tests are accessible 
and affordable to women who need them.”135 
The good news is the Court has defined the § 101 threshold inquiry, and decided that the 
hands of man must be clearly seen in an invention before the inventor may cross it. However, the 
Court has left inventors wondering: once an invention is eligible to cross the threshold, will §§ 
102, 103, and 112 be hiding behind the door waiting to slam it in their faces? As Myriad argued 
in their brief opposing certiorari, “the relevance of patenting isolated human DNA is ever 
diminishing in light of the publication of the entire human genome in 2001 . . . , thus presenting 
arguable bars to patentability under other provisions of the Patent Act (such as obviousness 
under § 103) for any claims to isolated human DNA molecules sought after that date.”136 This 
same argument will undoubtedly now be applied to cDNA. When the entire genome is mapped, 
and the methods and technology needed to produce complimentary versions are commonplace, 
where is the novelty? Further, is it not obvious to a person having ordinary skill in the art to 
produce these complimentary versions that are easier to work with? Only time will tell how the 
USPTO and the courts will handle these questions. 
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